“Preclinical Formulation for the Pharmacokinetics and Efficacy of GBO-006, a Selective Polo Like Kinase 2 (PLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer”. ADMET and DMPK, vol. 4, no. 4, Dec. 2016, pp. 314-26, https://doi.org/10.5599/admet.4.4.341.